Update in Medical Therapy of Ulcerative Colitis
- 1 August 2005
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Clinical Gastroenterology
- Vol. 39 (7), 557-569
- https://doi.org/10.1097/01.mcg.0000170735.43887.3a
Abstract
Recent advances in the pathogenesis of ulcerative colitis recognize the interface of genetic susceptibility, environmental factors (eg, gut microflora), and an altered host's immune response. The meteoric evolution of new therapies designed to address these pathogenetic factors may lead to confusing and often confounding treatment programs. This review is designed to assist the practitioner when in [corrected] incorporating new or novel therapies into a treatment program. These decisions are based on new clinical trial data and the experience of seasoned gastroenterologists with established remedies. NEWER CONCEPTS AND THERAPIES IN UC 5-ADA-- 1. Remains drug of choice for induction and maintenance of remission in mild to moderate IC.1,2 2. Rare but increased incidence of renal disease exists but benefits outweigh risks.18-20 3. Chemoprevention of colorectal cancer in UC is promising and may be related to higher dose and a lessened degree of inflammation.29-36 4. Bioequivalence of all USA 5-ASA is established. Choice of a 5-ASA preparation is not dependent on superiority of a particular mesalamine.3 Phosphodiesterase Inhibitor (OPC-6525)37: preliminary data promising Immunomodulators 6MP/AZA 1. long-term effect not waning51 2. concerns over lymphoma voiced but overall benefits outweigh risks64-70 3. 6MP metabolites measurements of increasing use52-56 Cyclosporine experience continues but serious adverse events remains.105-114 Biologics Infliximab--somewhat disappointing in CUC, awaiting RCT87-92 Basiliximab--useful as "steroid sensitizer" in previously steroid resistant patients118-120 Visilizumab--promising as alternative to cyclosporin in server U.C.115-117 Apheresis--and emerging "non-drug" treatment alternative121-135 Probiotics--Useful in pouchitis and some mild to moderate U.C.94-98, 154 ISIS topical therapy useful in early pilot study (pouchitis)151 Budesonide (pouchitis)147 Antibiotics (pouchitis)140-146 [corrected]Keywords
This publication has 102 references indexed in Scilit:
- Predictors of chronic pouchitisGastroenterology, 2003
- Efficacy and safety of a humanized α4β7 antibody in active crohn's disease (CD)Gastroenterology, 2003
- Multicenter randomized double blind controlled trial for ulcerative colitis therapy with leukocytapheresisGastroenterology, 2003
- Comparison of heparin and steroids in the treatment of moderate and severe ulcerative colitisGastroenterology, 2000
- Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitisGastroenterology, 1998
- Double-blind crossover trial of metronidazole versus placebo in chronic unremitting pouchitisDigestive Diseases and Sciences, 1994
- Pouchitis After Ileal Pouch-Anal Anastomosis: A Pouchitis Disease Activity IndexMayo Clinic Proceedings, 1994
- Increased risk of large-bowel cancer in Crohn's disease with colonic involvementThe Lancet, 1990
- Coated Oral 5-Aminosalicylic Acid Therapy for Mildly to Moderately Active Ulcerative ColitisNew England Journal of Medicine, 1987
- Treatment of Crohn's Disease with 6-MercaptopurineNew England Journal of Medicine, 1980